Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abituzumab - Merck Serono

Drug Profile

Abituzumab - Merck Serono

Alternative Names: Anti-CD51 antigen mAb; Anti-integrin alphaV mAb; DI 17E6; EMD525797

Latest Information Update: 16 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EMD Serono; Merck Serono
  • Developer Merck Serono; SFJ Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Systemic scleroderma
  • Discontinued Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 16 Aug 2019 Phase-II clinical trials in Colorectal cancer in USA (IV) (SFJ Pharmaceuticals pipeline, August 2019)
  • 02 May 2018 Merck enters into a agreement with with SFJ Pharmaceuticals to develop abituzumab through a novel risk-sharing collaboration agreement
  • 11 Jan 2018 Merck and EMD Serono discontinues phase-II clinical trials in Systemic scleroderma in USA, Spain, United Kingdom, Poland, Italy, Israel, Canada, Australia, Argentina (IV) (NCT02745145)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top